Investing.com - Financial Markets Worldwide

DaVita HealthCare Partners Inc (DVA)

NYSE
Symbol
Exchange
Currency
DVA·NYSE·USD
1DVA·Milan·EUR
DVA·TradeGate·EUR
Currency in USD
151.32
+5.27(+3.61%)
Closed·
After Hours
150.94-0.38(-0.25%)
·
DVA Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 13 days
Fair Value
Unlock Value
Day's Range
146.78151.85
52 wk Range
131.76179.60
Key Statistics
Edit
Prev. Close
146.05
Open
147.37
Day's Range
146.78-151.85
52 wk Range
131.76-179.6
Volume
1.2M
Average Volume (3m)
801.97K
1-Year Change
4.35%
Book Value / Share
-3.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DVA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
159.15
Upside
+5.17%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 10
High shareholder yield
Unlock InvestingPro

DaVita HealthCare Partners Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

DaVita HealthCare Partners Inc Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Industry
Healthcare Providers & Services
Sector
Healthcare
Employees
76000
Market
United States

DaVita HealthCare Partners Inc SWOT Analysis

Kidney Care Titan
DaVita, a $10.43B market cap leader in U.S. kidney care, faces growth challenges amid strong financials and a complex healthcare landscape
Financial Resilience
Despite treatment volume hurdles, DaVita consistently beats earnings expectations, boasts a 17% free cash flow yield, and trades near 52-week lows
Regulatory Tailwinds
Explore how ESRD rate revisions and new phosphate binder reimbursement policies could potentially boost DaVita's revenue by over $50 million
Growth Projections
Analysts forecast EPS of $11.32 for FY2025 and $12.18 for FY2026, with DaVita projecting 3-7% operating income growth for 2025
Read full SWOT analysis

DaVita HealthCare Partners Inc Earnings Call Summary for Q1/2025

  • DaVita beats Q1 2025 EPS forecast with $2.00 vs $1.96, revenue at $3.22B slightly above estimates; stock dips 0.38% after hours
  • Company maintains full-year EPS and operating income guidance despite challenges from cyber incident and severe flu season impact
  • Q1 saw decline in U.S. treatments per day by 40 basis points; strong international performance, particularly in Latin America
  • $680M in stock repurchased; CEO emphasizes resilience amid challenges and expects variability in transition throughout the year
  • Anticipates increased debt expenses of ~$145M per quarter; profitability from phosphate binders expected at upper end of guidance
Last Updated: 12/05/2025, 22:48
Read Full Transcript

Compare DVA to Peers and Sector

Metrics to compare
DVA
Peers
Sector
Relationship
P/E Ratio
12.8x−0.6x−0.5x
PEG Ratio
0.86−0.050.00
Price/Book
−41.3x0.9x2.6x
Price / LTM Sales
0.9x0.9x3.2x
Upside (Analyst Target)
7.5%47.8%42.7%
Fair Value Upside
Unlock17.7%5.8%Unlock

Analyst Ratings

1 Buy
8 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 159.15
(+5.17% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
2.00 / 1.96
Revenue / Forecast
3.22B / 3.20B
EPS Revisions
a
a
Unlock
Last 90 days

DVA Income Statement

People Also Watch

NVR
7,899.8
NVR
-0.12%
Moody’s
507.88
MCO
+1.76%
Adobe
372.46
ADBE
-0.11%
Aon
357.28
AON
+0.86%
PayPal
76.68
PYPL
+0.89%

FAQ

What Stock Exchange Does DaVita Trade On?

DaVita is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for DaVita?

The stock symbol for DaVita is "DVA."

What Is the DaVita Market Cap?

As of today, DaVita market cap is 11.44B.

What Is DaVita's Earnings Per Share (TTM)?

The DaVita EPS (TTM) is 10.37.

When Is the Next DaVita Earnings Date?

DaVita will release its next earnings report on 04 Aug 2025.

From a Technical Analysis Perspective, Is DVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has DaVita Stock Split?

DaVita has split 3 times.

How Many Employees Does DaVita Have?

DaVita has 76000 employees.

What is the current trading status of DaVita (DVA)?

As of 23 Jul 2025, DaVita (DVA) is trading at a price of 151.32, with a previous close of 146.05. The stock has fluctuated within a day range of 146.78 to 151.85, while its 52-week range spans from 131.76 to 179.60.

What Is DaVita (DVA) Price Target According to Analysts?

The average 12-month price target for DaVita is USD159.14667, with a high estimate of USD186 and a low estimate of USD145. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +5.17% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.